Satellos Bioscience Inc ICOTF

Primary Symbol: T.MSCL Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc > This Decline is shocking

<< Previous

Bullboard Posts

Next >>

Comment by AcynicalJedion Jul 24, 2018 7:53pm

147 Views

Post# 28362184

RE:This Decline is shocking

Jaytee123 wrote: .275 to .12 in 9 trading days?

Is it really? ICO hasn't even started phase 2 trials yet. Sure results from phase 1 were positive. But phase to is where therapies either make it or break it. This simply got way ahead of itself. If the bleeding stops and SP consolidates here it's still looking at a 130% gain on good phase 1 news which seems pretty reasonable. Give this another 6-12 months and "If" phase 2 yields favorable results you could certainly be looking at a multi dollar SP possibly much more.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing